
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna's strong outlook is supported by promising clinical data, particularly in its oncology pipeline, demonstrating significant efficacy with satisfactory safety profiles, including no severe adverse effects reported. The company aims to achieve substantial cost reductions of $1.4 to $1.7 billion by 2027 and has reiterated its goal to break even by 2028, enhancing its financial stability. Additionally, Moderna's commitment to advancing mRNA technology across diverse therapeutic areas positions it well for long-term revenue growth and increased market share within the biotech industry.
Bears say
The negative outlook on Moderna's stock is primarily driven by concerns regarding diminishing revenue growth potential from COVID vaccine sales due to waning vaccination rates. Additionally, the firm faces significant competitive challenges with its respiratory vaccine candidates, particularly against established competitors such as Arexvy and Abrysvo, which could limit commercial opportunities. Finally, the overall pipeline progress outside of respiratory vaccines is progressing slowly, further exacerbating revenue uncertainty in both short and medium-term projections.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares